A US Court of Appeals ruling has opened the door for Banner Life Sciences’ Bafiertam (monomethyl fumarate) delayed-release capsules, upholding a decision that the proposed product does not infringe “the extended portion” of a method-of-use patent shielding Biogen’s $3.3bn Tecfidera (dimethyl fumarate) brand.
In January this year, a Delaware district court ruled that Banner’s hybrid 505(b)(2) new drug application product, which currently holds...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?